National Bank of Canada FI Increases Stake in Sanofi (NASDAQ:SNY)

National Bank of Canada FI boosted its stake in shares of Sanofi (NASDAQ:SNY) by 2.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 303,934 shares of the company’s stock after purchasing an additional 6,089 shares during the period. National Bank of Canada FI’s holdings in Sanofi were worth $14,659,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. HighPoint Advisor Group LLC grew its holdings in shares of Sanofi by 7.2% during the fourth quarter. HighPoint Advisor Group LLC now owns 8,985 shares of the company’s stock valued at $433,000 after buying an additional 601 shares during the last quarter. Franklin Resources Inc. lifted its position in Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock worth $182,164,000 after acquiring an additional 369,530 shares during the period. CIBC Private Wealth Group LLC grew its stake in Sanofi by 19.8% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,175 shares of the company’s stock valued at $156,000 after purchasing an additional 525 shares during the last quarter. Transamerica Financial Advisors Inc. increased its holdings in shares of Sanofi by 20.7% in the fourth quarter. Transamerica Financial Advisors Inc. now owns 5,747 shares of the company’s stock valued at $278,000 after purchasing an additional 987 shares during the period. Finally, Intrust Bank NA raised its stake in shares of Sanofi by 5.2% in the fourth quarter. Intrust Bank NA now owns 27,978 shares of the company’s stock worth $1,349,000 after purchasing an additional 1,391 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SNY shares. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Stock Down 4.8 %

SNY stock opened at $51.98 on Friday. The firm’s fifty day moving average is $55.37 and its 200 day moving average is $52.71. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. Sanofi has a one year low of $45.22 and a one year high of $60.12. The firm has a market cap of $131.92 billion, a PE ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts forecast that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.